Forte Biosciences (FBRX) Net Income towards Common Stockholders (2016 - 2026)
Forte Biosciences (FBRX) reported Net Income towards Common Stockholders of -$22.1 million for Q1 2026, down 41.39% year-over-year from -$37.8 million in Q1 2025, and down 169.75% quarter-over-quarter from $31.7 million in Q4 2025.
Forte Biosciences (FBRX) Net Income towards Common Stockholders (2016 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has 11 years of Net Income towards Common Stockholders data on file, last reported at -$22.1 million in Q1 2026.
- Net Income towards Common Stockholders for Q1 2026 came in at -$22.1 million, down 41.39% year-over-year; the trailing twelve-month figure through Mar 2026 was -$20.4 million (down 33.07% YoY), and the FY2025 annual result was $3.1 million, up 110.06% from the prior year.
- Net Income towards Common Stockholders fell to -$22.1 million in Q1 2026 per FBRX's latest filing, from $31.7 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $31.7 million in Q4 2025 and troughed at -$22.1 million in Q1 2026.
- A 5-year average of -$5.3 million and a median of -$7.8 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2023 and 2024: Net Income towards Common Stockholders plunged 199.14% in 2023, then jumped 441.65% in 2024.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$4.9 million in 2022, then slipped by 29.2% to -$6.4 million in 2023, then jumped by 441.65% to $21.8 million in 2024, then soared by 45.57% to $31.7 million in 2025, then slumped by 169.75% to -$22.1 million in 2026.
- Business Quant data shows FBRX's Net Income towards Common Stockholders at -$22.1 million in Q1 2026, $31.7 million in Q4 2025, and -$18.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Forte Biosciences | 70.77 Mn | 12.55 Mn | - | -22.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.14 Mn |
| Dec 31, 2025 | 31.74 Mn |
| Sep 30, 2025 | -18.38 Mn |
| Jun 30, 2025 | -11.58 Mn |
| Mar 31, 2025 | -15.66 Mn |
| Dec 31, 2024 | 21.80 Mn |
| Sep 30, 2024 | -8.63 Mn |
| Jun 30, 2024 | -12.82 Mn |
| Mar 31, 2024 | -7.80 Mn |
| Dec 31, 2023 | -6.38 Mn |
| Sep 30, 2023 | -10.22 Mn |
| Jun 30, 2023 | -9.03 Mn |
| Mar 31, 2023 | -6.86 Mn |
| Dec 31, 2022 | -4.94 Mn |
| Sep 30, 2022 | -3.42 Mn |
| Jun 30, 2022 | -3.02 Mn |
| Mar 31, 2022 | -2.51 Mn |
| Dec 31, 2021 | -3.30 Mn |
| Sep 30, 2021 | -7.70 Mn |
| Jun 30, 2021 | -5.75 Mn |